Amgen presented phase 1 clinical trial data of its new anti-obesity drug candidate ‘AMG133’ at the World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases (WCIRDC) held in Los Angeles on the 3rd.
In this study, 110 obese adults with a BMI of 30 or more and less than 40 who did not suffer from diabetes were randomly administered ‘AMG133’ in various doses, once a month, along with a placebo for 12 weeks. As a result of the interim analysis of the test, the highest dose ‘AMG133’ administration group maintained the weight loss effect for about 70 days, and the average weight decreased by 14.5%. In some of them, weight loss of about 11.2% was maintained even after 150 days of the last administration. The most common adverse reaction of ‘AMG133’ was nausea or vomiting, but most were mild and disappeared within a few days after the first dose.
What stands out is that ‘AMG133’ proved its superiority in weight loss and maintenance ability compared to ‘Wigobi’ and ‘Maunjaro’. ‘Wigobi’ and ‘Maunjaro’ showed an average weight loss effect of 6% and 9%, respectively, for 12 weeks in a phase 1 study. In addition, while these drugs had to be administered once a week, ‘AMG133’ maintained its weight loss effect for up to five months.
Therefore, there is an analysis that if the development of ‘AMG133’ goes smoothly, it can emerge as a dark horse that can threaten existing strong players in the global obesity treatment market.
‘AMG133’ is the first GLP-1/GIPR dual agonist in its class that acts dually on GLP-1 and gastric motility inhibitory polypeptide (GIPR) receptors. It acts on GLP-1 but has a mechanism of antagonizing GIP, as opposed to ‘Maunjaro’. Amgen plans to initiate phase 2 clinical trials of ‘AMG133’ in the first half of next year.
Some criticize that regardless of the efficacy of ‘AMG133’, Amgen has joined the obesity treatment market too late and will not have a significant impact on the market. Some industry experts said, “Novo Nordisk and Lilly are showing promising efficacy in diabetes as well as obesity, but ‘AMG133’ only proved effective in weight loss.” predicted that
JP Morgan analyst Chris Schott predicted, “Even if everything goes well, the phase 3 clinical study of ‘AMG133′ will begin in 2024, and health authorities’ approval will come after that, in 2026 or 2027.” .
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.
*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!